Treatment
Platinum clinical trials
We’re tracking 239 recruiting studies that include Platinum, each written for real people, not researchers, below.
Recruiting studies
- NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Mobile, AlabamaAges 18 years+ - NCT06483048RecruitingPhase 1
MUC1-targeted T cells for relapsed ovarian cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called MUC1 on ovarian cancer cells. It is for people with ovarian cancer that has come back or is resistant to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT04055649RecruitingPhase 2
Test of ONC201 and weekly paclitaxel for platinum-resistant ovarian cancer
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Detroit, MichiganAges 18 years+ - NCT05538091RecruitingPhase 2
Testing vismodegib plus atezolizumab for platinum-resistant ovarian cancer
This Phase 2 trial tests whether combining vismodegib with atezolizumab can slow or shrink platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It targets cancers that grow again within 6 months after platinum chemotherapy.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07564141RecruitingPhase 3
New Drug for Recurrent Ovarian Cancer After Chemotherapy
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
Danbury, ConnecticutAges 18 years+ - NCT07225270RecruitingPhase 3
Study of Rina-S plus care for ovarian cancer maintenance
This trial tests whether adding Rina-S to standard maintenance therapy helps prevent cancer from returning in people with recurrent platinum-sensitive ovarian cancer who have responded to second-line platinum-based chemotherapy.
Miami, FloridaAges 18 years+ - NCT06463665RecruitingPhase 2
Virus therapy with chemo and immunotherapy for advanced lung cancer
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Bullhead City, ArizonaAges 18 years+ - NCT06730347RecruitingPhase 2
Study of lorigerlimab for advanced ovarian and other cancers
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06930794RecruitingPhase 3
Study of Vebreltinib Plus Chemo for MET-Positive Lung Cancer
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07322653Recruiting
Supplements to improve fitness in older adults with muscle loss
This study tests whether a special drink (MediDrink Platinum+) and a bean protein supplement can help improve fitness and muscle strength in older adults who are malnourished and have muscle loss. If you are 60 or older, underweight, and have lost muscle, this trial may offer a way to see if these supplements can help you get stronger.
BudapestAges 60 years+ - NCT04585958RecruitingPhase 1
Combination treatment for HER2-positive cancers and resistant ovarian cancer
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07321015RecruitingPhase 2
Fluzoparib after platinum for advanced triple-negative breast cancer
This trial tests the PARP inhibitor fluzoparib as a maintenance treatment for women with advanced triple-negative breast cancer whose disease responded or stabilized after platinum-based chemotherapy. The goal is to see if taking fluzoparib daily can delay cancer growth.
TianjinAges 18–75 - NCT05920356RecruitingPhase 3
Tested KRAS-targeted sotorasib plus chemo vs pembrolizumab plus chemo
This Phase 3 trial tests whether sotorasib plus standard chemotherapy works better than pembrolizumab (an immunotherapy) plus standard chemotherapy as first treatment for certain advanced lung cancers. It may help people whose tumors have a KRAS G12C mutation and that do not show PD-L1 on testing.
Santa Barbara, CaliforniaAges 18–100 - NCT05225363RecruitingPhase 1
CAR T therapy for ovarian cancer that no longer responds to platinum
This Phase 1 study tests a one-time treatment made from your immune cells (CAR T) to attack a protein found on some ovarian cancer cells. It is for people whose ovarian cancer has come back or worsened after platinum chemotherapy, aiming to see safety and early signs of benefit.
Duarte, CaliforniaAges 18 years+ - NCT07604766RecruitingPhase 3
Rina-S for platinum-resistant ovarian cancer in China
This study tests a new cancer drug called Rina-S (an antibody-drug conjugate, which is a targeted therapy that delivers medicine directly to cancer cells) compared to standard treatment options for ovarian cancer that has returned or worsened after platinum chemotherapy. The trial is specifically for patients in China whose cancer is resistant to platinum drugs.
ChangchunAges 18 years+ - NCT06434610RecruitingPhase 2
Study of B013 plus paclitaxel for ovarian cancer
This study tests a new drug (B013) combined with a standard chemotherapy (paclitaxel) for people with ovarian cancer that has come back after platinum-based treatment. The goal is to see if the combination works better than the current options.
BeijingAges 18–75 - NCT06686030RecruitingPhase 2
AK112 with chemo or olaparib for platinum-sensitive ovarian cancer
This trial tests a new drug called AK112 combined with chemotherapy or another drug (olaparib) for people with ovarian cancer that came back more than 6 months after platinum treatment. The goal is to see if these combinations work better than current options.
WuhanAges 18 years+ - NCT05998135RecruitingPhase 2
Testing Atovaquone for Platinum-Resistant Ovarian Cancer
This trial tests whether a drug called atovaquone, already used for other conditions, can help people with ovarian cancer that no longer responds to platinum chemotherapy. It aims to find a new treatment option for this hard-to-treat type of cancer.
Atlanta, GeorgiaAges 18 years+ - NCT06169956Recruiting
Study of nivolumab with chemo before lung cancer surgery
This study looks at how well the immunotherapy drug nivolumab (Opdivo) works when given with standard chemotherapy before surgery for people with a certain type of lung cancer that has not spread. It may help shrink the tumor before surgery.
Kempten (Allgäu), BavariaAges 18 years+ - NCT05416775RecruitingPhase 1/Phase 2
Test drug SHR-8068 for advanced lung cancer
This trial tests SHR-8068 in people with advanced non-small cell lung cancer (NSCLC). It may help by controlling cancer after standard treatments have not worked, and it’s designed to find the right way to give the drug.
Hefei, AnhuiAges 18–75 - NCT06841679RecruitingPhase 2/Phase 3
Testing utidelone plus chemo for untreated stomach cancer
This trial tests a new capsule (utidelone) combined with standard chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. It aims to see if this combination works better than current options.
Hialeah, FloridaAges 18 years+ - NCT06687070RecruitingPhase 1
APG-2449 alone or with PLD for advanced cancers
This trial tests a new drug, APG-2449, either alone or with another chemotherapy called PLD (pegylated liposomal doxorubicin). It is for people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT07229625RecruitingPhase 3
New drug combination for advanced bile duct cancer
This trial is testing whether a new drug (SHR-8068) combined with adebrelimab and chemotherapy works better than the current standard treatment for people with advanced bile duct cancer who have not been treated yet.
Hangzhou, ZhejiangAges 18–75
What Platinum is being studied for
Conditions with recruiting Platinum studies.
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Platinum-resistant Ovarian Cancer
- Platinum-sensitive Ovarian Cancer
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Refractory Ovarian Carcinoma
- Platinum-resistant Recurrent Ovarian Cancer
Common questions
- Are there clinical trials studying Platinum?
- Yes. Clin2 currently lists 239 recruiting studies that include Platinum, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Platinum trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Platinum an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Platinum or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.